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ABSTRACT  
 
Background: UK deaths due to chronic liver diseases such as cirrhosis have quadrupled 
over the last 40 years, making this condition now the third most common cause of premature 
death. Most patients with advanced cirrhosis (end–stage liver disease, [ESLD]) develop 
ascites. This is often managed with diuretics, but if refractory then the fluid is drained from 
the peritoneal cavity every 10-14 days by large volume paracentesis (LVP), a procedure 
requiring hospital admissions. As the life expectancy of patients with ESLD and refractory 
ascites (if ineligible for liver transplantation) is on average ≤ 6 months, frequent hospital visits 
are inappropriate from a palliative perspective. One alternative is long-term abdominal drains 
(LTAD), used successfully in patients whose ascites is due to malignancy. Although inserted 
in hospital, these drains allow ascites management outside of a hospital setting. LTAD have 
not been formally evaluated in patients with refractory ascites due to ESLD. 
 
Methods: Due to uncertainty about appropriate outcome measures and whether patients 
with ESLD would wish or be able to participate in a study, a feasibility randomised controlled 
trial (RCT) was designed. Patients were consulted on trial design. We plan to recruit 48 
patients with refractory ascites and randomise them (1:1) to either a) LTAD or b) current 
standard of care (LVP) for 12 weeks. Outcomes of interest include acceptability of LTAD to 
patients, carers and healthcare professionals as well as recruitment and retention rates. 
Palliative care Outcome Scale (IPOS), the Short Form Liver Disease Quality of Life (SF-
LDQOL), the EuroQol (EQ-5D) and carer (Zarit Burden Interview [ZBI-12]) reported 
outcomes will also be assessed. Preliminary data on cost effectiveness will be collected and 
patients and healthcare professionals will be interviewed about their experience of the trial 
with a view to identifying barriers to recruitment. 
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Discussion: LTAD could potentially improve end-of-life care in patients with refractory 
ascites due to ESLD by improving symptom control, reducing hospital visits and enabling 
some self-management. Our trial is designed to see if such patients can be recruited, as well 
as informing the design of a subsequent definitive trial. 
 
Trial registration:  ISRCTN30697116, date assigned: 07/10/2015   
 
Keywords: ASCITIC FLUID, END STAGE LIVER DISEASE, PARACENTESIS, 
PERMANENT INDWELLING PERITONEAL CATHETER, PALLIATIVE CARE, HEALTH 
RELATED QUALITY OF LIFE, QUALITY ADJUSTED LIFE YEARS, HEALTHCARE 
ECONOMICS 
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BACKGROUND 
UK deaths due to chronic liver disease such as cirrhosis have quadrupled over the last 40 
years, making this condition the third most common cause of premature death. [1] Ascites - 
an abnormal accumulation of fluid in the peritoneal cavity - is present in up to 90% of patients 
with advanced cirrhosis [2-3], resulting in frequent hospitalisations due to debilitating 
episodes of pain and breathlessness. In the early stages, this condition can be managed 
using diuretic therapy, but as the condition progresses (end-stage liver disease, [ESLD]) the 
ascites becomes unresponsive to medical treatment. In the absence of liver transplantation, 
a diagnosis of refractory ascites confers a median life expectancy of ≤ 6 months. [3-5]  
End-of-life care in patients with ESLD and refractory ascites has not been a research priority. 
Over 70% of patients with ESLD die in hospital [6], a figure substantially – and in our view 
unacceptably - higher than that of 40% for patients with terminal cancer. [7] The most 
common palliative management for refractory ascites due to ESLD is large volume 
paracentesis (LVP), performed every 10-14 days. [3] This involves a costly 24-48 hour 
hospital admission, insertion of a temporary abdominal drain and removal of up to 15 L of 
ascitic fluid over 4-6 hours. There is simultaneous administration of intravenous 4.5% or 20% 
(w/v) human albumin solution, 8g -10g per 1L of ascitic fluid removed. [3] Consequently, 
patients often delay the hospital visits until their ascites is tense and painful [8], so reducing 
their quality of life (QOL). [9] Individuals with refractory ascites often have contraindications 
to alternative invasive procedures such as transjugular intrahepatic portosystemic shunt 
(TIPS) [10] and or the automated low flow ascites (ALFA) pump. [11]   
In this feasibility randomised controlled trial (RCT) we will investigate the use of a simple and 
less invasive device, the long-term abdominal drain (LTAD), in patients with refractory 
ascites due to ESLD. This technique involves placing a tunnelled drain through the 
abdominal wall under local anaesthetic and with ultrasound guidance. Once the drain is in 
place, the patient’s ascites can be drained in the patient’s usual place of residence. 
Community nurses, or (where willing), carers can then remove smaller volumes (1-2 L) of 
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ascitic fluid in about 5-10 minutes, usually 2-3 times a week dependent on patient 
preference. These devices have been extensively utilised in patients whose ascites is due to 
advanced malignancy and have been shown to be both clinically and cost-effective, with low 
complication rates and improved quality of life (QOL). [12-14] In terms of palliative care in  
refractory ascites due to ESLD there may be additional benefits including the involvement of 
patients and carers in the management of this condition, reduced complications through the 
regular removal of smaller volumes of fluid, and, importantly, reduced stigma associated with 
hospital-based LVP (voiced to us as a concern by service users). 
Given the relative success of these devices in patients with ascites due to malignancy there 
is a clear need for a RCT in ESLD and refractory ascites comparing palliative LTAD to 
current standard care (LVP), with end-of-life QOL and cost-effectiveness as major outcomes. 
LTAD have not been specifically assessed in patients with ESLD because of the potentially 
increased risks of bleeding (due to coagulopathy) [15] and infections, specifically 
spontaneous bacterial peritonitis. [16,17]  
There are additional concerns related to this specific patient group. We do not know whether 
such individuals would be able or even willing to participate in a RCT, given their potentially 
higher prevalence of alcohol and substance misuse and other psychosocial issues. Similarly, 
there is uncertainty as to the most appropriate assessment tools and outcome measures. 
Finally, given the complex end of life care needs of this cohort, concerns remain to patients, 
carers and healthcare professionals (HCP) over a strategy that moves care away from the 
hospital to the community. To address these issues we have designed a feasibility study to 
inform the development of a subsequent definitive RCT. 
 
METHODS 
Aim, design and setting of the study  
 
The aim of this study is to assess the feasibility of conducting a future RCT of the safety, 
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clinical-effectiveness and cost-effectiveness of refractory ascites management using LTAD 
against current standard of care (LVP) in patients with ESLD when liver transplant is not an 
option. This document is based on v6.0 of the protocol (13/10/2017). This multicentre trial 
has been designed in accordance with phase 2 of the Medical Research Council (MRC) 
Complex Interventions Framework [18] and the Method Of Researching End of Life Care 
guidance (MORECare). [19]  
This feasibility RCT is being conducted both at a hospital (The Royal Sussex County Hospital 
[RSCH], Brighton, Sussex, UK and the Princess Royal Hospital [PRH], Hayward’s Heath, 
Sussex, UK, both part of the Brighton and Sussex University Hospital [BSUH] National 
Health Service [NHS] Trust; Worthing Hospital, Worthing, Sussex, UK [Western Sussex NHS 
Foundation Trust], Plymouth Hospitals NHS Trust, Plymouth, UK, Blackpool Victoria 
Hospital, Blackpool, UK [Blackpool Hospitals NHS Foundation Trust] and Southampton 
General Hospital,  Southampton, UK [University Hospital Southampton NHS Foundation 
Trust]) and a community setting (The Sussex Community Trust). Those randomised to LTAD 
will be followed up in the community. This three-year study is planned to run from Sept 2015 
until Sept 2018. 
 
Characteristics of participants   
Patients will be identified from acute medical units, outpatients and Gastroenterology and  
Hepatology wards. They will be approached for the study at the participating centres by the 
research team after having been identified by the local medical team as being potentially 
eligible.  
Inclusion criteria 
1. Age ≥18 years, with no upper age limit. 
2. Untreatable (refractory) ascites defined as:  
a. Ascites that is unresponsive to fluid and sodium restriction and high 
dose diuretic treatment (spironolactone 400 mg/day and/or 
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furosemide 160 mg/day) and/or intolerance of diuretics [20, 21]. 
b. Ascites that recurs rapidly after LVP (requiring one or more LVP/ 
month). 
3. Child-Pugh Score [22] of ≥9 unless specifically decided by the medical team 
that they are to receive only palliative treatment.  
4. Registered with a General Practitioner (GP) in the Community Trusts 
serving the participating centres. 
5. Ability to speak, read and understand English. 
6. Capacity to give written informed consent as assessed by using a Capacity 
to Consent Checklist (see additional files) 
Exclusion criteria 
1. Loculated or chylous ascites. 
2. Presence of > grade 1 hepatic encephalopathy (specified by West Haven 
Criteria. [23]  
3. Evidence of active infection, which in the Investigator’s opinion would 
preclude insertion of LTAD e.g. bacterial peritonitis. Such patients could be 
reconsidered for inclusion in the trial if infection has been successfully 
treated.  
4. Eligible for liver transplantation, in the opinion of the Hepatology multi- 
disciplinary team (MDT) and according to national guidelines. [24] 
5. Psychosocial issues which, in the medical team’s opinion, would preclude 
engagement with the trial, such as posing a risk to the safety of oneself or 
the research team.  
As this is a feasibility study we will not specifically exclude patients based on abnormal 
haemostasis measurements. Consistent with local practice, those individuals with platelet 
count of < 50x109 and/or an International Normalised Ratio (INR) of > 1.7 will be given blood 
and/or clotting products prior to receiving LTAD or LVP. 
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Potential participants can be considered for inclusion in this trial even if they are currently 
participating in another research study, as long as their medical team are confident that 
participation in the current trial would be logistically feasible and not unduly onerous for the 
participants.  
While we would prefer that potential carers/consultees are identified for each participant, 
their absence will not preclude study participation. 
 
Consent  
Suitable participants will be identified by the usual medical teams. A research team member 
(to include Chief Investigator [CI], co-investigators, Principal Investigators [PI], Nurse and 
Research Fellow) will provide patient information sheets (PIS) to potential research 
participants and give an explanation about the study including ascites management.  
Patients will be provided at least 48 hours to read the PIS. If willing, consent will be obtained 
in hospital by a research team member. If the research team is the usual medical team, to 
avoid any potential conflict of interest, potential participants will be discussed at the weekly 
liver multidisciplinary meeting (MDM). Capacity to give informed consent will be carefully 
assessed (see inclusion criteria).  In the event that capacity is lost during the trial, the 
participant’s nominated consultee will be approached to determine whether the participant 
should continue in the study. If a consultee has not been nominated or is unavailable then 
the participants usual medical consultant, (independent from the research team), will be 
consulted to decide whether it is in the participant’s best interests to continue in the study. 
 
Randomisation 
Patients who fulfil the inclusion and exclusion criteria and give written informed consent to 
participate in this trial will be randomised on a 1:1 basis to either Group 1: LTAD or Group 2: 
LVP (current standard of care). The allocations will be made by minimising on 1) centre, 2) 
Child-Pugh Score and 3) gender. No stratification will be utilised. Minimisation will 
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be implemented using an independent system hosted at Kings Clinical Trials Unit 
KCTU). Patients will be enrolled by the research team member who will log into the web 
based system, enter patient ID number, recruiting site, gender and Child Pugh Score. The 
system will automatically generate a confirmation email informing the research team of the 
outcome of allocation. 
Patients will be followed up for 12 weeks. With the participants agreement we will inform their 
GP about their participation in the trial. 
 
Interventions 
 
Group 1: LTAD 
There are two LTAD currently available in the UK: the PleurX™ (UK Medical Ltd, 
Basingstoke, UK [25] and the Rocket® (Rocket Medical, Watford, UK. [26] We have chosen 
to use the Rocket device (Figure 1) [26] primarily because our local clinicians and community 
nursing teams are already familiar with them. Rocket Medical already have an established 
training and support programme for local community nurses and care homes. In addition, our 
earlier experience [27] suggests that the Rocket devices are easier to insert than the 
PleurX™ devices, and require less expensive consumables that can currently be prescribed 
by community practitioners. 
 
Procedure for insertion of LTAD  
Insertion of the LTAD will be performed in hospital in a side room, using bedside ultrasound 
guidance. Insertion will only be performed if, within the week leading up to planned LTAD 
insertion, haemostatic function (including INR and platelet count) has been checked and 
blood products administered as necessary. Where INR is > 1.7, patients will receive up to  
two volumes of fresh frozen plasma (FFP) transfused according to patient weight and INR, 
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immediately prior to drain insertion. Where the platelet count is ≤50x109, patients will be 
given one to two pools of platelets immediately prior to insertion of the drain. 
To ensure consistency, it would be ideal that all LTAD are inserted at one site (RSCH), but if 
not possible due to patient preference or logistic issues they will be inserted at local sites, 
usually by an interventional radiologist.  
The Rocket® LTAD will be inserted using a combination of tunnelled and Seldinger 
technique as stated in the Rocket® information sheet. [26] After confirming the location of the 
insertion site using bedside ultrasound and skin preparation with Chloraprep™ (chlorhexidine 
gluconate and isopropyl alcohol), local anaesthetic (up to 10 ml 1% or 2% lidocaine) will be 
administered to the incision site and along the proposed tunnel tract. A small incision is 
made where the catheter will enter the abdominal cavity. The introducer needle will be 
inserted through the incision into the peritoneal cavity and a guide wire is passed through the 
needle, which will then be removed. A second incision (exit site) will be made approximately 
5 cm medial from the first, where the catheter will exit the tunnel. The catheter will be 
tunnelled from exit site incision to the first incision site with the tunneller, making sure that the 
cuff is mid-way between the first and second incision sites. A split-sheath dilator will be then 
passed over the guide wire, and the inner dilator and guide wire removed leaving the split 
sheath in situ.  
The tunneller is then removed from the catheter, which is then passed through the split 
sheath, separating the split sheath ensuring that all of the catheter is contained within the 
peritoneum. The last piece of the split-sheath is then removed. The catheter is then adjusted 
along the tunnel, so the cuff moves towards the exit site, ensuring that any kinks are 
removed from the catheter. Finally, both incision sites will be sutured (avoiding the catheter) 
and a dressing applied. 
Participants will receive antibiotic prophylaxis (ciprofloxacin 500 mg/day) or an equivalent 
antibiotic (if contraindication to ciprofloxacin) or dependant on local practice. 
We will provide guidance to the participant and carer (where present) on how to use the 
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LTAD, based on the information previously supplied in the PIS. Participants will also be given 
an information sheet provided by Rocket Medical. [26] Participants will be referred to their 
community nursing service. A Rocket Medical Discharge letter will be sent to their GP and 
the community nursing team. Rocket Medical will also be informed so that they can organise 
any further support/training for patients, carers, and community nurses. In addition, we will 
arrange for drainage bags to be delivered directly to the participant’s usual place of 
residence on request by the community nurses.  
The community nurses will visit the participants in their homes and either perform the 
drainage procedure themselves, or supervise the drainage of ascites. The frequency of these 
visits will depend on the participant’s ascites-related symptoms, but work in ascites due to 
malignancy [28] indicates that two to three visits each week is most commonly required, with 
approximately 1-2 L of ascites being drained each time. It is recommended that drainage 
frequency not exceed 3 times per week. In the event that participants and/or carers wish to 
perform self-drainage, they will be trained to do so by the community nurse.  
The Integrated Primary Care Team (IPCT) will closely monitor trial participants allocated to 
the LTAD arm. We expect that this will happen 2-3 times a week if the community nurses are 
performing ascitic fluid drainage.  
For participants who live in a care home or move to a care home (with or without nursing), 
the follow-up procedure would be the same as for patients who live at home. In such cases 
we would seek approval from the care home managers. For those requiring hospice care, 
this would be a temporary stay since hospices do not generally provide long-term care.  
Again, permission will be sought from the hospice team to visit the participants for follow up 
and only if such visits remain acceptable to the participants.  
 
Group 2 Standard Care (LVP) 
Participants randomised to LVP [3], the current standard of care, will be admitted to hospital 
as either a self-referral or via their GP, whichever is current local practice. They will undergo 
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LVP as clinically indicated. LVP involves the insertion of a peritoneal drain for up to 6 hours, 
and removal up to 15 L of ascites. If the total volume of fluid to be removed is > 5 L, 
intravenous 4.5% or 20% (w/v) human albumin solution 8g -10g per 1L of ascitic fluid 
removed, will be administered. [3]     
As with Group 1, participants will receive antibiotic prophylaxis (ciprofloxacin 500 mg once a 
day or an equivalent antibiotic (if any contraindication to ciprofloxacin) or dependent on local 
practice). 
For both groups there will be fortnightly visits with a research team member for questionnaire 
based and clinical assessments as well as routine clinical blood samples (see below). We 
anticipate that these two weekly contacts will improve adherence to the protocol. 
 
Clinical Follow up   
While participating in this trial, for no individual will routine clinical care be modified or denied 
whether in the community, primary care or hospital setting. This will include symptomatic 
relief for pain (including use of opioids), shortness of breath, confusion (hepatic 
encephalopathy), jaundice or itching. Use of diuretics will be permitted in both groups. As is 
the current standard of care in patients with ESLD, use of certain drugs (e.g. non-steroidal 
anti-inflammatory drugs, aminoglyosides) will be contraindicated. [3]  
Palliative care needs and concerns will be reassessed at each visit for each participant using 
the integrated palliative outcome scale (IPOS) questionnaire [29] (see below).  If a high level 
of specialist palliative care need is identified (as defined within a distress protocol standard 
operating procedure [SOP]), through the IPOS questionnaire, a research team mini MDM 
(either face-to-face or virtual) will be convened to agree the most appropriate way forward. 
As is usual clinical practice, referrals to a specialist service by the usual healthcare providers 
can also occur irrespective of any trial assessments or advice.  If that occurs, consistent with 
standard practice, a referral is simultaneously made to a community (district) nurse, if not 
already done for another reason.  
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It may become necessary, after discussion with the CI and the Trial Management Group 
(TMG), to remove the LTAD. Reasons for this could include 1) patient request, 2) Serious 
Adverse Reaction (SAR) assessed by the CI as being directly related to the LTAD, 3) 
significant deviation from the study protocol with potential for harm (for example participant 
not allowing community nurses to enter residence to perform drainage). 
The contact telephone numbers for key members of the research team will be provided to 
the participants. Out of hours, participants will be encouraged to contact their GP or attend 
the accident and emergency department of their local hospital, as per usual standard of care.  
 
Outcome measures 
The objectives of this feasibility study therefore are to explore: 
• Properties of different outcome measures (specifically health resource utilisation and QOL 
instruments) to ascertain the most appropriate primary outcome for the full trial and use the 
chosen primary outcome measure to inform sample size calculations from estimates of the 
standard deviations, for the full trial.  
• Resource implications of LTAD compared to standard of care (LVP), including a preliminary 
assessment of cost-effectiveness to indicate whether a full trial is worthwhile 
• The number of eligible patients  
• The extent of HCP support in identifying possible participants 
• Symptom burden in patients with ESLD and refractory ascites 
• Informal carer/family perceived burden (if appropriate) 
• Whether patients are willing to be randomised to LTAD, rather than LVP 
• Acceptability of and adherence to home ascites drainage 
• Attrition rates, including attrition due to death, illness or other causes 
• Complication rates 
• Willingness to participate in a qualitative interview (optional) 
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• Acceptability of LTAD to patients, carers and clinical staff using qualitative methods  
(optional) 
• Acceptability of questionnaires  
We will therefore collect data on a range of candidate primary outcome measures, including 
QOL and health resource utilisation. The primary outcome measure(s) for the definitive trial 
will be decided by the research team, including service users, on review of the final analysis 
of this feasibility study. 
Study success criteria will include  
a. Percentage of study period time in hospital for LTAD group is < 50% 
of that for the LVP group (where the study period time is the number 
of days from date of LTAD insertion to the end of the study period or 
the patient’s death (whichever is earliest); time spent in hospital is 
the number of bed days used)  
b. Attrition rate is not > 50%  
c. There is <10% overall rate of LTAD removal due to one or more of 
the following complications: peritonitis, failed insertion, bleeding and 
blockage  
d. 80% of questionnaires and qualitative interviews completed by each 
patient.  
 
Data collection 
Data will be collected on an electronic Case Report Form (eCRF), using the MACRO 
electronic data capture system provided by KCTU and hosted on the KCL server. The 
system is compliant with Good Clinical Practice (GCP), with a full audit trail and formal 
database lock functionality.  
Figure 2 shows participant timeline/study flow chart 
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Schedule of Assessments (Figure 2 and SPIRIT Figure 3) 
The research team member will visit participants at home every two weeks for questionnaire 
based and clinical assessments (see below) as well as collection of routine clinical blood 
samples. The amount and frequency of drainage and other pertinent observations will be 
recorded by community nurses in a formal study diary, as is the case when LTAD is used in 
patients with ascites due to malignancy. The research team member will train and advise the 
community nurses and participants on data collection to reduce the possibility of missing 
data.  
 
Questionnaire-based assessments 
The questionnaire-based assessments will be performed by the research team member and 
depending on patient preference, done either face to face at the patient’s home or via phone 
(within three days of the research team member visit). The research team member will follow 
guidance in the lone worker policy when conducting home/usual place of care visits.  
We have selected questionnaires validated with our population group (e.g. palliative care 
patients, and those with ESLD). Some, like the Integrated Palliative care Outcomes Scale 
(IPOS) [29] (see below), are short, relatively brief to complete and have a proxy version if a 
patient loses capacity during the study. As this is a feasibility study we will explore the 
acceptability of the measures used. We will pilot the patient questionnaires comprising the 
proposed measures with the first 8 patients to explore and assess patient fatigue and time 
taken for completion.  We will review the pilot findings and amend the patient questionnaire 
schedule if indicated, submitting the required Research Ethics Committee (REC) amendment 
for all proposed changes. The research team member will assist the participants in 
completion of the questionnaires if needed and if specifically requested by the participant. If 
participants are too unwell, the questionnaires can be filled by proxy by the carers, both to 
reduce the participant burden as well as risk of missing data. Additionally, those patients 
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allocated to the LVP group, if the hospital visits coincides with questionnaire assessments, 
the assessments can be done at that point in hospital.  
 
Symptom distress and concerns 
The IPOS [29-31] combines the Palliative care Outcome Scale (POS) and POS-S 
(symptoms). It is a measure frequently used in palliative care research and clinical practice 
[29-33]. These are validated for clinical practice, audit and research and can be used in any 
setting. POS-S captures physical symptom specific information, and, “other” symptoms 
specific to liver disease/ascites can be added e.g. abdominal bloating. A SOP will be 
implemented when clinical and/or risk of harm issues are identified to ensure timely 
assessment by their usual healthcare providers and/or referral to a specialist palliative 
service depending on needs identified.  
A staff version of IPOS will be used in case participants are unable to complete the 
questionnaire. IPOS will be assessed at baseline and two weekly and takes less than 10 
minutes to complete (a total of 10 questions). 
 
Quality of Life (QOL)  
QOL will be assessed using the Short Form Liver Disease Quality of Life (SF-LDQOL) [34-
35], a reliable and valid measure of health related QOL in patients with advanced liver 
disease awaiting transplant, incorporating a core QOL assessment and disease targeted 
items. As specific QOL assessment tools are lacking in cirrhosis, the SF-LDQOL is the most 
appropriate option and was selected after service user involvement. The original SF-LDQOL 
questionnaire has 43 questions though questions from 26 onwards are for the purposes of 
validating the questionnaire and not specific to the SF-LDQOL itself. [34-35] The authors 
have provided a scoring algorithm that includes only the first 25 questions, therefore only 
these will be used. This questionnaire takes about 15 minutes to complete and will be 
assessed at baseline and four weekly. 
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Health economics outcome   
There are opposing views on use of EQ-5D as a composite measure of Quality-Adjusted Life 
Years (QALYs) in palliative care [19]. However, it is the most widely used indicator and until 
valid alternatives are available, we have elected to assess EQ-5D-5L, [36] (at baseline and 
four weekly) in this feasibility study for its utility as an outcome. The EQ-5D-5L has six 
questions and will take about 5 minutes to complete. 
 
Impact on carers  
For those willing to participate, the Zarit Burden Interview (ZBI-12) [37-38] will be employed 
at baseline and four weekly. This measures family/informal carer appraisal of the impact of 
caregiving. It has 12 items, is easy to administer and can be used in the hospital or 
community setting, taking about 10 minutes to complete. 
 
Service use assessment  
For each arm of the feasibility study, a comprehensive patient level database of services 
used will be collated, including all inpatient, outpatient, emergency, primary, community, 
social and voluntary services, equipment and supplies and assistance from family/informal 
carers. For community and home based services, a modified version of the ambulatory and 
home care record (AHCR) [39] will be used and administered by the research team member 
at baseline and two weekly. The carers will assist with this especially if the participant is too 
unwell. The AHCR, a standardised and comprehensive framework and tool, measures 
resources used within the end-of-life context from a societal perspective. This approach 
gives equal consideration to costs borne by the health system as well as those costs borne 
by care recipients and informal caregivers, such as family members and friends. It will take 
about 20 minutes to complete. Self-reported data will be verified and supplemented (e.g. for 
supplies) with reference to nursing records.  Data on all hospital use will be gathered from 
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hospital records at the end of the study using a purposefully designed in-house proforma. 
Service use will be converted to costs using national sources [40] and NHS reference costs. 
Informal care will be valued using replacement cost methods, and applying the tariff for 
community support workers.  
A feasibility study gives us the opportunity to test out candidate patient reported outcome 
measures with the intention of only taking the most useful measures through to any definitive 
study. Survey fatigue was always a concern for the research team and our service users  
and the issue also arose during the Ethical Committee review process. Therefore we had a 
safety check to reassess survey fatigue after the first eight patients were recruited. We have 
found no evidence of any problems so far; indeed some patients restate their willingness to 
complete the questionnaires. 
 
Qualitative interviews 
Qualitative data will be collected as part of a concurrent embedded strategy. [41] Interview 
themes will include an exploration of: experiences of recruitment, participation, LTAD/LVP 
and end of life care; beliefs about the role and value of LTAD in refractory ascites, and 
practical steps and barriers involved in undertaking LTAD.  
Twenty-eight optional interviews (20 participants and 8 clinical key informants) will be 
undertaken by a qualitative researcher, with additional support if needed. Clinicians and 
research participants will be identified and recruited via the research team member. Patient 
recruitment will seek to reach a maximum diversity sample of participants, i.e. interview 
participants with a wide range of demographic characteristics, with purposive sampling (if 
feasible), informed by the IPOS (given that the cohort are living with deteriorating health). 
The research team member will invite patients to participate in the qualitative interview study 
and will seek permission to pass contact details (normally telephone number) to qualitative 
researcher. The qualitative researcher will contact participants to arrange a convenient time 
for the interview. As life expectancy in refractory ascites due to ESLD is on average six 
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months, the qualitative interview methodology seeks to explore a wide range of patient 
experiences, recognising that participant beliefs and experiences may change across this 
period. Interviews will, therefore, be divided into two phases: 
 
Phase 1 (week 0-8): 12 patients (6 from each arm), 4 clinical staff 
Phase 2 (week 9-12):   8 patients (4 from each arm), 4 clinical staff 
 
In the event of inability to recruit new participants for Phase 2 interviews, additional 
participants or repeat interviews will be sought during Phase 1. Interviews with key clinical 
staff will follow the same aims of patient interviews and will be anonymous (i.e. key 
Informants will be asked to withhold patient identities). 
Interviews will take place at participants’ homes or by phone according to participant 
preference and geographical location. Clinical staff will be interviewed at their place of work 
or at a mutually convenient venue. Consent will be taken from all participants, including any 
carer requested by the participant to be present.  For telephone interviews, consent will be 
taken verbally and recording will be started before telephone consent is taken, so that the 
verbal consent can be recorded as a separate file from the interview. Signed consent forms 
will be kept for five years. Interview data will be transcribed and the audio version 
deleted. The anonymised transcription of the interview (including the verbal consent) will be 
stored (labelled with patient study number). 
To reduce participant burden, breaks will be allowed during the interviews if requested by the 
participants and interviews will last between 20 and 60 minutes. 
 
Safety Monitoring  
A monitoring plan will be put in place and adhered to for each research site (see additional 
files). Monitoring visits will be undertaken by the BSCTU on behalf of the Study Sponsor. The 
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study may be audited in line with the BSCTU or by the Sponsor requirements. Audits will be 
conducted by personnel independent from the research team. 
Common terminology criteria for adverse events (AE) (CTCAE, version 4.03 [42] will be used 
when assessing AE and serious adverse events (SAEs). As this is a feasibility study all AE 
and SAE will be recorded in the source data and reported on the electronic case record form 
(eCRF). Crucially, only those SAEs that in the opinion of the CI are related to the study 
intervention (LTAD) will be reported in an expedited manner to the Brighton and Sussex 
Clinical Trials Unit (BSCTU).  
This feasibility RCT is investigating LTAD in a cohort with ESLD. By its very nature, this is a 
group with high morbidity and mortality. Hence in this patient population worsening of 
existing conditions, hospitalisations, acute illnesses and deaths are expected. These events 
will be recorded in the eCRF but not reported to BSCTU or the REC.  
Expected/unexpected unrelated AE/SAE will include but not limited to: 
• Hepatic encephalopathy 
• Gastrointestinal bleeding related to peptic ulceration, hypertensive portal gastropathy or 
varices 
• Liver cancer and or its treatment  
• Complications of gastroscopy (perforation, bleeding) 
• Complications of LVP (circulatory and or electrolyte disturbances, bleeding, bowel 
perforation, failed drainage)   
• Complications of drug treatment for cirrhosis (lactulose, beta blockers, terlipressin, 
antibiotics, diuretics) 
• Death related to the liver disease - will include death from liver failure, multiorgan failure, 
variceal bleeding and sepsis 
 
Expected serious adverse reactions (SAR)  
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If in the CI’s opinion a SAR is considered directly related to the LTAD and is an expected 
SAR then this will be recorded on the eCRF and reported to the BSCTU immediately 
following the Safety Reporting SOP. Expected SAR will include the following (but only if they 
result in hospitalisation): 
• Failure of LTAD insertion   
• Drain leakage or blockage  
• Cellulitis  
• Bleeding  
• Pain at site of insertion not controlled by analgesia  
• Spontaneous bacterial peritonitis 
• Sepsis which in the opinion of the CI is directly related to LTAD 
• Death which in the opinion of the CI directly related to the LTAD 
 
Suspected unexpected, serious adverse reactions (SUSAR)  
This will include all SARs that in the opinion of the CI are directly related to the intervention 
and are not listed as a known (expected) SAR. All SUSARs that occur between insertion of 
the LTAD and three months post insertion or death, whichever is earlier, will be recorded on 
the eCRF form and emailed/faxed to BSCTU immediately, at least within 24 hours of the 
research team becoming aware in accordance with the BSCTU Safety Reporting SOP. The 
Research Ethics Committee will be notified of any SUSAR to the study intervention by the 
BSCTU. For each SUSAR, all relevant information will be collected and they will be followed 
up until resolved or a final outcome reached.  
The CI will have direct and ultimate responsibility for reviewing all reported SARs and 
SUSARs and will ensure that BSCTU reports these appropriately according to the BSUH 
SOP on Safety Reporting in Non-CTIMP studies. 
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DATA ANALYSIS 
Statistical analysis  
Guidelines for feasibility studies suggest that analysing 12 participants in each arm will 
provide an adequate sample size with which to achieve our objectives. [43] However, since 
this is a cohort with a poor prognosis, attrition is likely to be high. In our pilot study of seven 
patients [27], survival post insertion ranged from 6 to 96 days (though LTAD were inserted 
late in the disease trajectory). Due to the advanced disease stage of the participants we are 
assuming a 50% attrition. The sample size will therefore be increased to 24 participants in 
each arm, i.e. a total recruitment target of 48 participants. This sample size will be adequate 
to inform the research methods for a definitive phase 3 RCT.  
Recruitment rate will be evaluated in terms of the proportion of eligible patients that provide 
informed consent. Attrition at all stages will be recorded, particularly due to unwillingness or 
inability to manage LTAD as this is an indication of acceptability. Data will be analysed on 
available cases in the groups to which they were randomised. We will present these data as 
a flow chart. The amount of missing data will be summarised for each variable but there will 
be no imputation. As this is a feasibility study, stopping rules will not be defined. 
The flow of patients through the trial is depicted in the CONSORT diagram (Figure 4). [44]  
Descriptive statistics will be used to summarise and compare the quantitative outcome 
measures to include a) complication rates :failed insertion, drain leakage or blockage, 
cellulitis, bleeding, pain at site of insertion not controlled by analgesia, peritonitis, sepsis and 
death (the latter two only if directly related to LTAD), b) symptoms: IPOS, QOL (SF-LDQOL, 
EQ-5D-5L) [29, 34-36] and c) carer burden [37-38] for each arm. Means and standard 
deviations will be determined for normally distributed outcomes and medians and 
interquartile ranges for skewed outcomes at the different time points and at the end of the 
study. Analyses will use all available cases following intention-to-treat principles. 95% 
confidence intervals will be calculated for parameter estimates as appropriate. Prior to the 
analysis of the data, a detailed statistical analysis plan will be written and signed off. 
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Health economics data analysis  
The economic analysis will adopt the perspectives of the health and social care systems.   
Using the patient-level database assembled from participant self-report and hospital and 
community nursing records, the feasibility study will identify the main resource items for 
which comprehensive data collection would be required in the main trial.  Interactions 
between ascites management and other palliative care services will be explored.  In 
particular, community nurse visits in both groups will be monitored so extra visits required for 
LTAD, compared to normal care, which was a major source of uncertainty in the earlier 
modelling study, can be identified. [13] The group mean total costs of services used in 
ascites management will be compared between LTAD and LVP. 
The properties of the main clinical outcomes (IPOS, SF-LDQOL, EQ-5D-5L) [29,34-36] and 
the number of hospital days will be investigated to assess their value as measures of 
effectiveness for the definitive trial so that a primary outcome can be determined.  Data on 
QALYs from EQ-5D-5L [36] will be investigated for possible use in the economic evaluation. 
A preliminary cost-effectiveness analysis will be undertaken to determine the likely 
advantage of conducting a full trial. [45] Sensitivity analysis will be performed by varying the 
key cost drivers, such as the number of inpatient days and the cost of bed days.              
 
Qualitative data analysis  
If purposive sampling is not feasible, the proportion of participants choosing to participate in 
qualitative interviews will be noted. Interviews will be audio recorded and labelled using the 
same anonymous study number as the intervention component of this study. The same 
number will be used so that in the event of a participant reporting a serious concern about 
their condition or their care, the qualitative researcher can raise this with the patient's 
clinician. In this unlikely event, the researcher will inform the patient of the need to convey 
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this information to their clinician. The qualitative researcher will have access to the clinical 
study data of the individual if needed. 
Thematic analysis supported by qualitative software (NVivo) [46] will be used to extract 
overarching themes from the interviews to capture patients' experiences and beliefs. Utilising 
the process of triangulation [47] the findings of the qualitative arm will be used to inform the 
quantitative results, particularly in the context of QOL and experience of end of life care 
provision. 
Data will be analysed in a blinded manner. However, the research team members collecting 
information from the patients will always be aware of their allocation since a high level of 
scrutiny is necessary to ensure that there are no safety events in the LTAD group. Our 
service users were also insistent that participants not engage with multiple members of the 
research team, further excluding blinded data collection.  
 
ANCILLARY AND POST-TRIAL CARE 
 
At the end of the trial, participants will continue to be assessed by their usual medical care 
team. Those allocated to the LTAD arm will have the option, if they so wish, to continue with 
the LTAD under care of their usual Consultant Gastroenterologist/Hepatologist. 
 
COMMITTEES  
Trial Management Group (TMG) 
This will be constituted of the CI, all co-investigators and Principal Investigators (PIs), 
Research Fellow, trial manager, data manager and statistician and will be chaired by the CI 
(SV).  
The TMG will meet every month to:  
1. Finalise trial-related materials.  
2. Oversee and co-ordinate the various aspects of the project, so that the research 
completes on time and on budget. 
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3. Assess study progress to ensure that recruitment is on target and on budget. If 
recruitment is below that anticipated then strategies to improve this will be discussed. 
4. Assess adherence to protocol by reviewing protocol deviation logs.  
 
Data Safety Monitoring Committee (DSMC) 
This will be an independent committee chaired by Professor Guruprasad Aithal, (Professor of 
Hepatology, Nottingham University NHS trust), with two other independent members, 
Professor Bobbie Farsides, (Chair of Medical Ethics at BSMS) and Professor Martin Llewelyn 
(Professor in Infectious Diseases, BSMS and Hon Consultant, BSUHT), as well as at least 
one Service User member. Study data report will be provided to the DSMC by the trial 
manager every 10-12 months for the first two years and then every 6 months for the last 
year, in accordance with the Terms of Reference for the Committee. The DSMC will meet as 
above to address any safety concerns, review any ethical issues raised and monitor adverse 
events. The DSMC will make recommendations to the TMG as appropriate, and has the 
power to stop the trial if necessary. The DSMC will be independent of the Study Sponsor. 
Details of IDMC Charter can be obtained from trial.monitors@bsuh.nhs.uk 
 
DISCUSSION 
The impetus for the REDUCe trial was driven by our concerns that patients with ESLD 
receive suboptimal end of life care compared to those with other terminal conditions. Most 
individuals with ESLD almost always die in hospital [6] while receiving end-of-life care even 
though in many cases palliative care provided within the community would be more 
appropriate and compassionate. Such an option is often not feasible due to the complex end 
of life needs of patients with ESLD (including LVP) and the fluctuating disease trajectory 
making it difficult to define when a palliative phase has been reached. [6,48] Most patients 
with ESLD develop ascites [2-3] and the management strategy in ESLD is thus often dictated 
by this specific symptom. Our own data suggests that approximately 40% of patients with 
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ascites requiring LVP can go on to develop refractory ascites [49]. This condition has a major 
impact on the QOL in ESLD, due to factors such as direct physical discomfort but also the 
need for recurrent hospitalisation for LVP. [3,50] We would argue that for many such 
individuals these recurrent hospitalisations impair their QOL. A more appropriate option 
would be to focus on holistic palliative care in the community, based on discussions on future 
wishes. [50-51] This will require a multidisciplinary approach to the disease, reflected in the 
composition of the REDUCe study team.    
Consistent with the lack of research in this complex cohort of individuals and therefore not 
unexpectedly, recruitment to this trial has been challenging. We found that clinicians who 
were not part of the study team were often reluctant, particularly in younger patients, to 
diagnose ESLD and discuss the implications of a limited life expectancy and purely palliative 
management. In some instances prospective participants were only identified late and 
unfortunately died before they could make an informed decision about trial participation. The 
patients themselves are often vulnerable and (in their opinion) disenfranchised and 
stigmatised. Finally, setting up new sites for a study that spans both acute hospital and 
community settings, often without existing research collaborations, has been difficult and 
time consuming. 
Conversely, we have already begun to note positive changes in attitudes, beliefs and 
practice of HCP locally and in the study sites. Simply by attempting to discuss the REDUCe 
trial we have seen a change in attitudes towards symptom control and QOL as well as timely 
referral to palliative care. There is also increasing recognition that patients should be able to 
be more involved in decisions about their end of life care. This trial has raised the local 
profile of these under-researched patients, with wider recognition of the need for MDT 
communication and collaboration. Specifically, many local hospitals now discuss all patients 
with ESLD at a weekly liver MDM so as to identify in a timely manner those that are entering 
the palliative phase of their disease. This has undoubtedly driven the improvement in 
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recruitment. The NIHR acknowledging this and the potential of this study to result in a 
paradigm shift in end of life care in ESLD have granted a funded extension for a year. 
 
AUTHORSHIP ELIGIBILITY GUIDELINES  
Authorship credit will be provided to those individuals that have made a significant 
contribution to the trial concept, design, data acquisition, interpretation and analysis, drafting 
the manuscript including intellectual content and critical revisions. Therefore the CI, co-
investigators, Research Fellow, members of the BSCTU and all PIs at participating sites will 
be eligible for authorship credit. However, as is current accepted practice, it will be 
unacceptable for PIs to independently publish data of individuals that they have recruited for 
the study. No data will be released prior to first presentation and or publication without the 
explicit knowledge and consent of the CI. After discussion at TMG, it may be deemed 
appropriate to present interim results at local, national and international meetings and 
conferences. 
 
DISSEMINATION PLAN 
Results of this study will be disseminated via local (Regional British Society of 
Gastroenterology), national (British Association for Study of Liver) and international 
(American Association for the Study of Liver Diseases and European Association for the 
Study of the Liver) meetings. Further dissemination will occur via palliative care conferences 
(UK Palliative Care Congress, European Association of Palliative Care World Congress, 
American Academy of Hospice and Palliative Medicine Annual Assembly) and regional 
research networks and end of life groups. We plan to publish our research in high impact  
Hepatology and Palliative Care journals. Our service user members will play a vital role in 
research dissemination. We also anticipate providing evidence to the National Institute for 
Health and Care Excellence (NICE). 
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TRIAL STATUS 
 Now open, with 36 patients recruited as of May 2018. Funded extension obtained May 2017. 
 
PROTOCOL AMENDMENTS  
The need for protocol amendments will be discussed by the TMG and submitted to Sponsor 
for determination of substantial/non-substantial amendment. Substantial amendments will be 
submitted to the Health Research Authority (HRA) for review. Once a favourable opinion has 
been given, the BSCTU will be responsible for notifying local sites of the amendment and 
ensuring the PI/CI are aware when the implementation can occur.  
 
CONFIDENTIALITY  
In line with BSUH trust policy and the 1998 Data Protection Act, any data collected as part of 
this trial will be kept strictly confidential. All study data will either be held on secure university 
and hospital computers or in a secure and locked location at BSCTU. Initially patient 
identifiers will be utilised during randomisation, but subsequently all research participants will 
be allocated a unique study number that will be recorded on all other data collection forms. 
Only those individuals directly involved with the research will have access to the study data.  
 
NON-STANDARD ABBREVIATIONS 
AE                 Adverse event 
AHCR  Ambulatory and Home Care Record 
AMA   Antimitochondrial antibody 
ANA   Antinuclear antibody 
ALFA            Automated low flow ascites 
BSCTU Brighton and Sussex Clinical Trials Unit 
BSMS  Brighton and Sussex Medical School 
BSUH  Brighton and Sussex University Hospital 
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CI  Chief Investigator 
CLD  Chronic liver disease 
CTIMP          Clinical Trial of an Investigational Medicinal Product  
ESLD  End-stage liver disease 
eCRF            Electronic case record form  
GP                General Practitioner 
GCP              Good Clinical Practice 
HCP              Healthcare Professional  
HRA              Health Research Authority 
HBsAg Hepatitis B surface antigen 
HCV  Hepatitis C Virus 
HIV  Human Immunodeficiency Virus 
INR  International Normalised Ratio 
IPCT  Integrated Primary Care Team 
IPOS  Integrated Palliative care Outcome Scale 
KCL  Kings College London 
KCTU  Kings College London Clinical Trials Unit 
LKM   Liver kidney microsomal antibody  
LTAD  Long-term abdominal drain 
LVP  Large volume paracentesis 
MDM  Multidisciplinary meeting 
MDT             Multidisciplinary team 
MRC  Medical Research Council 
NHS  National Health Service 
NIHR  National Institute of Health Research 
PIS                Patient information sheet 
POS  Palliative Outcome Score 
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POS-S Palliative Outcome Score (Symptom list) 
PRH  Princess Royal Hospital 
PI                  Principal Investigator 
QALYs          Quality-Adjusted Life Years  
QOL              Quality Of Life 
R&D  Research & Development 
REC              Research Ethics Committee 
RfPB  Research for Patient Benefit 
SAR  Serious Adverse Reaction 
SAE               Serious Adverse Event 
SF-LDQOL Short Form Liver Disease Quality Of Life 
SMA   Smooth muscle antibody 
SOP              Standard operating procedure 
TIPS              Transjugular intrahepatic portosystemic shunt 
WSHFT West Sussex Hospital Foundation Trust 
ZBI-12 Zarit Burden Interview 
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Figure 1 Rocket Long-Term Abdominal Drain in situ [26] 
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Figure 2 Participant Timeline 
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Figure 3 SPIRIT Figure 3 
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Timepoint (weeks) - t0 t2 t4 t6 t8 t10 t12 
         
Capacity check         
Informed Consent1         
Demographics          
Medical History         
Eligibility according to inclusion/exclusion criteria         
Routine liver ultrasound2          
Research blood sample for storage  3       
Liver screen blood tests4         
Blood and urine culture, urine dipstick testing5         
Randomisation6         
Alcohol and substance misuse assessment         
Liver disease scores          
Routine haematology and biochemistry         
Diagnostic paracentesis7          
Liver disease assessment and history         
Adverse event review         
Concomitant medication review         
Examination and vital signs8         
LTAD insertion (or LVP)         
Drainage assessment (both LTAD and LVP)         
Questionnaires: IPOS, AHCR         
Questionnaires: SF-LDQOL, EQ5D-5L, ZBI-12          
 Questionnaire: Hospital service use         
 Qualitative interviews                 Phase 1      Phase 2     
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Figure 4 Consort Flow Chart  
 
 
 
